Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 2.39 USD -3.24% Market Closed
Market Cap: 498.7m USD
Have any thoughts about
Sangamo Therapeutics Inc?
Write Note

Sangamo Therapeutics Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sangamo Therapeutics Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sangamo Therapeutics Inc
NASDAQ:SGMO
Cash & Cash Equivalents
$39.2m
CAGR 3-Years
-39%
CAGR 5-Years
-19%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%
No Stocks Found

Sangamo Therapeutics Inc
Glance View

Market Cap
498.6m USD
Industry
Biotechnology

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO Intrinsic Value
2.49 USD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Sangamo Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
39.2m USD

Based on the financial report for Sep 30, 2024, Sangamo Therapeutics Inc's Cash & Cash Equivalents amounts to 39.2m USD.

What is Sangamo Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
13%

Over the last year, the Cash & Cash Equivalents growth was -31%. The average annual Cash & Cash Equivalents growth rates for Sangamo Therapeutics Inc have been -39% over the past three years , -19% over the past five years , and 13% over the past ten years .

Back to Top